YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Rahim, Said ^a   Beauchamp, Elspeth M ^a   Kong, Yali ^a   Brown, Milton L ^a   Toretsky, Jeffrey A ^a   Üren, Aykut ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MESSENGER RNA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR ER81; TRANSCRIPTION FACTOR ERG; UNCLASSIFIED DRUG; YK 4 279; DNA BINDING PROTEIN; ERG PROTEIN, HUMAN; ETV1 PROTEIN, HUMAN; INDOLE DERIVATIVE; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR; YK 4-279;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; CANCER CELL; CANCER INVASION; CELL FUSION; CELL MOTILITY; CELL TYPE; CONTROLLED STUDY; DRUG TARGETING; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MALE; NONHUMAN; PROSTATE CANCER; TRANSCRIPTION REGULATION; TRANSIENT EXPRESSION; ANIMAL; CELL STRAIN COS1; CERCOPITHECUS; CHROMATIN IMMUNOPRECIPITATION; DRUG SCREENING; GENETICS; KINETICS; METABOLISM; METHODOLOGY; PROSTATE TUMOR; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; CHROMATIN IMMUNOPRECIPITATION; COS CELLS; DNA-BINDING PROTEINS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INDOLES; KINETICS; MALE; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS;

EID: 79955779109     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019343     Document Type: Article

References (25)

1. Demichelis F, Fall K, Perner S, Andren O, Schmidt F, et al. (2007) TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 26: 4596-4599.
2. Nam RK, Sugar L, Wang Z, Yang W, Kitching R, et al. (2007) Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression. Cancer Biol Ther 6: 40-45.
3. Rajput AB, Miller MA, De Luca A, Boyd N, Leung S, et al. (2007) Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J Clin Pathol 60: 1238-1243.
4. Soller MJ, Isaksson M, Elfving P, Soller W, Lundgren R, et al. (2006) Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. Genes Chromosomes Cancer 45: 717-719.
5. Tu JJ, Rohan S, Kao J, Kitabayashi N, Mathew S, et al. (2007) Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues. Mod Pathol 20: 921-928.
6. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, et al. (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310: 644-648.
7. Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, et al. (2007) Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 448: 595-599.
8. Seth A, Watson DK, (2005) ETS transcription factors and their emerging roles in human cancer. Eur J Cancer 41: 2462-2478.
9. Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, et al. (2008) Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 10: 177-188.
10. Cai C, Wang H, Xu Y, Chen S, Balk SP, (2009) Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer. Cancer Res 69: 6027-6032.
11. Erkizan HV, Kong Y, Merchant M, Schlottmann S, Barber-Rotenberg JS, et al. (2009) A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. Nat Med 15: 750-756.
12. Wei GH, Badis G, Berger MF, Kivioja T, Palin K, et al. (2010) Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo. EMBO J 29: 2147-2160.
13. Simbulan-Rosenthal CM, Trabosh V, Velarde A, Chou FP, Daher A, et al. (2005) Id2 protein is selectively upregulated by UVB in primary, but not in immortalized human keratinocytes and inhibits differentiation. Oncogene 24: 5443-5458.
14. Fingleton B, (2006) Matrix metalloproteinases: roles in cancer and metastasis. Front Biosci 11: 479-491.
15. de Launoit Y, Baert JL, Chotteau-Lelievre A, Monte D, Coutte L, et al. (2006) The Ets transcription factors of the PEA3 group: transcriptional regulators in metastasis. Biochim Biophys Acta 1766: 79-87.
16. Keese CR, Bhawe K, Wegener J, Giaever I, (2002) Real-time impedance assay to follow the invasive activities of metastatic cells in culture. Biotechniques 33: 842-844, 846, 848-850.
17. Jiang WG, Ablin RJ, Kynaston HG, Mason MD, (2009) The prostate transglutaminase (TGase-4, TGaseP) regulates the interaction of prostate cancer and vascular endothelial cells, a potential role for the ROCK pathway. Microvasc Res 77: 150-157.
18. Esquenet M, Swinnen JV, Heyns W, Verhoeven G, (1997) LNCaP prostatic adenocarcinoma cells derived from low and high passage numbers display divergent responses not only to androgens but also to retinoids. J Steroid Biochem Mol Biol 62: 391-399.
19. Hermans KG, van der Korput HA, van Marion R, van de Wijngaart DJ, Ziel-van der Made A, et al. (2008) Truncated ETV1, fused to novel tissue-specific genes, and full-length ETV1 in prostate cancer. Cancer Res 68: 7541-7549.
20. Toretsky JA, Erkizan V, Levenson A, Abaan OD, Parvin JD, et al. (2006) Oncoprotein EWS-FLI1 activity is enhanced by RNA helicase A. Cancer Res 66: 5574-5581.
21. Sun C, Dobi A, Mohamed A, Li H, Thangapazham RL, et al. (2008) TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene 27: 5348-5353.
22. Yu J, Mani RS, Cao Q, Brenner CJ, Cao X, et al. (2010) An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 17: 443-454.
23. Beauchamp E, Bulut G, Abaan O, Chen K, Merchant A, et al. (2009) GLI1 is a direct transcriptional target of EWS-FLI1 oncoprotein. J Biol Chem 284: 9074-9082.
24. Nasca MR, O'Toole EA, Palicharla P, West DP, Woodley DT, (1999) Thalidomide increases human keratinocyte migration and proliferation. J Inverst Dermatol 113: 720-724.
25. Dewor M, Steffens G, Krohn R, Weber C, Baron J, Bernhagen J, (2007) Macrophage migration inhibitory factor (MIF) promotes fibroblast migration in scratch-wounded monolayers in vitro. FEBS Letters 581: 4734-4742.